Five-Year Extended Hormone Therapy No Better in Breast Cancer
THURSDAY, July 29, 2021 -- Extending hormone therapy by five years does not provide benefit over a two-year extension among postmenopausal women with hormone receptor-positive breast cancer who had received five years of adjuvant endocrine therapy,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hormonal Therapy | Hormones | Pharmaceuticals | Women